PLUS THERAPEUTICS, Inc. Common Stock earnings per share and revenue
On Oct 30, 2025, PSTV reported earnings of -0.04 USD per share (EPS) for Q3 25, missing the estimate of -0.02 USD, resulting in a -96.08% surprise. Revenue reached 1.40 million, compared to an expected 1.53 million, with a -8.69% difference. The market reacted with a +2.45% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.03 USD, with revenue projected to reach 1.56 million USD, implying an decrease of -25.00% EPS, and increase of 11.66% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were PLUS THERAPEUTICS, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, PLUS THERAPEUTICS, Inc. Common Stock reported EPS of -$0.04, missing estimates by -96.08%, and revenue of $1.40M, -8.69% below expectations.
How did the market react to PLUS THERAPEUTICS, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 2.45%, changed from $0.53 before the earnings release to $0.54 the day after.
When is PLUS THERAPEUTICS, Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 25, 2026.
What are the forecasts for PLUS THERAPEUTICS, Inc. Common Stock's next earnings report?
Based on 6
analysts, PLUS THERAPEUTICS, Inc. Common Stock is expected to report EPS of -$0.03 and revenue of $1.56M for Q4 2025.